ClinicalTrials.gov
ClinicalTrials.gov Menu

BrUOG-EG-203 Cetuximab, Paclitaxel, Carboplatin and Radiation for Esophageal, Gastroesophageal Junction and Gastric Cancer

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT00439608
Recruitment Status : Completed
First Posted : February 23, 2007
Results First Posted : July 1, 2013
Last Update Posted : February 13, 2018
Sponsor:
Collaborator:
Bristol-Myers Squibb
Information provided by (Responsible Party):
howard safran, Brown University

Study Type: Interventional
Study Design: Intervention Model: Single Group Assignment;   Masking: None (Open Label);   Primary Purpose: Treatment
Conditions: Esophageal Cancer
Gastric Cancer
Intervention: Drug: Cetuximab,Paclitaxel, Carboplatin

  Participant Flow

Recruitment Details
Key information relevant to the recruitment process for the overall study, such as dates of the recruitment period and locations
60 patients were enrolled at multiple hospitals and medical clinics

Pre-Assignment Details
Significant events and approaches for the overall study following participant enrollment, but prior to group assignment
No text entered.

Reporting Groups
  Description
Treatment

Cetuximab, Paclitaxel, Carboplatin and Radiation for Esophageal, Gastroesophageal Junction and Gastric Cancer

Patients received cetuximab, 400 mg/mg2 over 2 h on Day 1 then 250 mg/m2/week over 1 h, for 5 additional weeks. Patients also received paclitaxel, 50 mg/m2/week, over 1 h and carboplatin AUC (area under the curve) = 2/week, over 30 min, for 6 weeks. Cetuximab was administered first. Patients were then monitored for 1 h. Paclitaxel was then administered followed by carboplatin. Radiation was generally administered after chemotherapy. Dexamethasone 20 mg intravenously (IV), diphenhydramine 50 mg IV, and ranitidine 50 mg IV were given 30 min before treatment. Dosages of dexamethasone and diphenhydramine could be reduced in subsequent weeks if no hypersensitivity reactions were observed.


Participant Flow:   Overall Study
    Treatment
STARTED   60 
COMPLETED   60 
NOT COMPLETED   0 



  Baseline Characteristics

Population Description
Explanation of how the number of participants for analysis was determined. Includes whether analysis was per protocol, intention to treat, or another method. Also provides relevant details such as imputation technique, as appropriate.
Patients received cetuximab, 400 mg/mg2 over 2 h on Day 1 then 250 mg/m2/week over 1 h, for 5 additional weeks. Patients also received paclitaxel, 50 mg/m2/week, over 1 h and carboplatin AUC (area under the curve) = 2/week, over 30 min, for 6 weeks. Cetuximab was administered first.

Reporting Groups
  Description
Treatment Cetuximab, paclitaxel, and carboplatin weekly for 6 weeks with 50.4 Gy radiation.

Baseline Measures
   Treatment 
Overall Participants Analyzed 
[Units: Participants]
 60 
Age 
[Units: Participants]
Count of Participants
 
<=18 years      0   0.0% 
Between 18 and 65 years      20  33.3% 
>=65 years      40  66.7% 
Age 
[Units: Years]
Mean (Standard Deviation)
 65  (5) 
Sex: Female, Male 
[Units: Participants]
Count of Participants
 
Female      10  16.7% 
Male      50  83.3% 
Region of Enrollment 
[Units: Participants]
 
United States   60 


  Outcome Measures

1.  Primary:   Reponse Rate at Time of Surgery by Tissue   [ Time Frame: within 30 days of last treatment ]

2.  Secondary:   Measure of Safety and Tolerability According to CTC Version 3.0   [ Time Frame: 30 days ]
Results not yet reported.   Anticipated Reporting Date:   No text entered.  


  Serious Adverse Events


  Other Adverse Events


  Limitations and Caveats

Limitations of the study, such as early termination leading to small numbers of participants analyzed and technical problems with measurement leading to unreliable or uninterpretable data
No text entered.


  More Information

Certain Agreements:  
Principal Investigators are NOT employed by the organization sponsoring the study.
There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed.


Results Point of Contact:  
Name/Title: Howard Safran, MD
Organization: BrUOG
phone: 401-863-3000
e-mail: Hsafran@lifespan.org



Responsible Party: howard safran, Brown University
ClinicalTrials.gov Identifier: NCT00439608     History of Changes
Obsolete Identifiers: NCT01904435
Other Study ID Numbers: BrUOG-EG-203
BMS#CA225091 ( Other Identifier: BMS )
First Submitted: February 22, 2007
First Posted: February 23, 2007
Results First Submitted: May 9, 2013
Results First Posted: July 1, 2013
Last Update Posted: February 13, 2018